• Insmed was removed from the NASDAQ-100 Index on 19 June 2026, even as attention intensified around its experimental lung therapies pipeline.
• Analyst commentary has recently emphasized upcoming data for Insmed’s TPIP lung drug as a potential catalyst that could reshape investor expectations.
• Next, we’ll examine how heightened anticipation around TPIP’s forthcoming data release may influence Insmed’s broader investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Insmed Investment Narrative Recap

To own Insmed, you need to believe its respiratory portfolio, led by brensocatib and TPIP, can justify today’s valuation despite ongoing losses. The NASDAQ 100 removal may affect sentiment and liquidity, but it does not change the central near term catalyst, which is the upcoming TPIP data, or the biggest current risk around regulatory and market access outcomes for brensocatib and ARIKAYCE.

Against this backdrop, Cantor Fitzgerald’s recent reiteration of its positive rating and higher price target highlights how much weight some analysts place on TPIP as a misunderstood catalyst. That view sits alongside Insmed’s ongoing efforts to expand ARIKAYCE’s label after positive ENCORE data, reinforcing how much of the story still hinges on clinical execution rather than index membership.

Yet even if TPIP delivers, investors still need to think carefully about the risk that...

Insmed's narrative projects $4.1 billion revenue and $1.0 billion earnings by 2029.

Uncover how Insmed's forecasts yield a $197.14 fair value, a 100% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts saw TPIP as part of a path to about US$5.2 billion in revenue and US$1.9 billion in earnings by 2029, which is a much more aggressive story than the consensus and could be tested by Insmed’s index exit and the possibility that TPIP’s concentrated Phase III program...

Explore 4 other fair value estimates on Insmed - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Insmed research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Insmed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insmed's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.